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Acute aortic syndromes (AASs) are deadly cardiovascular emergencies involving the thoracic aorta. 
AASs are relatively rare conditions, have unspecific signs and symptoms (including truncal pain, syncope, 
neurologic deficit and limb ischemia) and require contrast-enhanced tomography angiography (CTA) of the 
chest and abdomen for conclusive diagnosis and subsequent therapeutic planning. In the Emergency 
Department (ED), most patients with potential signs/symptoms of AASs are finally found affected by other 
alternative diagnoses. Hence, misdiagnosis and delayed diagnosis of AASs are major concerns. In critically ill 
patients, decision to perform CTA is usually straightforward, as exam benefits largely outweigh risks. In 
patients with ST-tract elevation on ECG, suspected primary ischemic stroke and in stable patients 
(representing the most prevalent ED scenarios), proper selection of patients necessitating CTA is 
cumbersome, due to concurrent risks of misdiagnosis and over-testing. Available studies support an 
algorithm integrating clinical probability assessment, bedside echocardiography and D-dimer (if the clinical 
probability is not high). Therapeutic management includes medical therapy for all patients including an opioid 
and anti-impulse drugs (a beta-blocker and a vasodilator), targeting a heart rate of 60 bpm and systolic blood 
pressure of 100-120 mmHg. Patients with AASs involving the ascending aorta are likely candidate for urgent 
surgery, and complicated type B AASs (severe aortic dilatation, impending or frank rupture, organ 
malperfusion, refractory pain, severe hypertension) necessitate evaluation for urgent endovascular 
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Acute aortic syndromes (AASs) are a group of diseases involving the thoracic aorta and sharing 
several etiological, pathological, clinical and therapeutic features. AASs include “classic” acute aortic 
dissection (AD), intramural aortic haematoma (IMH), penetrating aortic ulcer (PAU) and aortic rupture.[1, 2] 
AASs can develop after trauma, even in the absence of any pre-existing aortic disease. However, most cases 
of AASs are “spontaneous” and constitute a final catastrophe following long-standing and asymptomatic 
aortic tissue degeneration. 
AD begins with an intimal tear conveying blood into the medial layer. Through one or more additional 
intimal breaches, blood proceeds through both an aortic “false” lumen (FL, within the aortic wall) and the 
physiological aortic “true” lumen (TL).[1–3] Static, dynamic or embolic involvement of collateral arteries can 
lead to organ malperfusion. Disruption of the aortic adventitia causes haemorrhage in the surrounding 
anatomic spaces (mediastinum, pericardium, pleura). IMHs are caused by bleeding from vasa vasorum within 
the tunica media. Progression to the adventitia can lead to external haemorrhage, while inner progression 
may cause intimal ulceration and AD.[1–5] PAU is an atherosclerotic lesion with localized intimal tearing. PAU 
can also develop towards IMH, AD or rupture. 
The most common classifications of AASs are those by DeBakey and Stanford. DeBakey categorizes AASs 
in type I (involving ascending aorta, arch and descending thoracic aorta), type II (limited to ascending aorta) 
and type III (involving descending aorta distal to LSA origin). Stanford categorizes AASs in type A (involving 
ascending aorta) and type B (not involving ascending aorta). Most AAS-B are distal to the left subclavian 
artery (LSA), but also arch involvement with spared ascending aorta is common.[1–3] 
AASs are relatively rare. In the general population, they affect 5-15 cases/100.000 individuals/year. The 
median age of AD patients is 63 years, with 33.1% female and 86.4% white. AD accounts for approximately 
80% (67/33% A/B-type), IMH for 15% (35/60% A/B-type) and PAU for 5% of AASs. AASs are emergencies 
characterized by rapid evolvement towards severe morbidity and mortality. Classic studies indicate a 
mortality of 1-2% per hour in untreated patients. For patients receiving current therapeutic standards, in-
hospital mortality is 26/11.1% for AD-A/B, and 26.6/4.4% for IMH-A/B. Further 1-year mortality is 8.7/8.2% 
for AD-A/B and 5.3/10.3% for IMH-A/B.[4, 6–8] 
 
Predisposing factors 
Factors predisposing to AASs are summarized in table 1. They include conditions leading to pathological 
aortic remodelling and factors functioning as acute triggers.[1–3] In the ED practice, genetic conditions and 
vasculitis are rare. Since these patients are poorly represented in diagnostic studies, they should be managed 
as high-suspicion cases, as applicability of general rule-out protocols is largely unknown. Several patients 
with suspected AASs present a history of systemic arterial hypertension, thoracic aorta enlargement or 
aneurysm or previous aortic interventions. Recent pharmacological treatments may be relevant, as 
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fluoroquinolone use has been associated with increased incidence of AASs.[9] The prevalence of known 
atherosclerotic disease, diabetes and smoking habit is relatively lower in patients with AASs, as AD and IMH 
typically develop within non-atherosclerotic tissues. Therefore, presence of these conditions may relatively 
lower the pre-test probability of AAS, in favour of acute coronary syndromes. 
 
Clinical presentation and findings 
The acute clinical manifestations of AASs originate from one or more of the following pathological 
mechanisms (table S1): (1) aortic dilatation, (2) impending/frank rupture with external haemorrhage, (3) 
organ malperfusion, (4) inflammation and (5) congestive heart failure. Surviving patients will encounter 
continuous pathological aortic remodelling and dilatation, leading towards “classic” aneurysms, 
saccular/fusiform aneurysms or pseudoaneurysms.[1–3, 10]  
According to guidelines and good practice, red-flag symptoms that must lead to consider AASs in 
differential diagnosis (“think-aorta” code) are truncal pain (including neck), syncope, neurological deficit and 
limb ischemia. However, the overall accuracy of potential signs/symptoms of AASs is limited (table 2).[11–
13] In case-series and diagnostic studies, the most sensitive symptom is truncal pain (most frequently 
involving the chest and described as sudden or severe). However, truncal pain also represents amongst the 
most frequent complaints in ED practice (~6% of ED visits, 8-10 million/year in the US). Therefore, detailed 
information on the pain characteristics should be carefully explored, but absence of suggestive patterns only 
modestly reduces the pre-test probability of AAS. Higher spec is found for less common findings such as pulse 




Female sex is an important confounder for diagnosis of in AASs. Although women are less frequently 
affected, their outcome is worse, likely due to delayed diagnosis and atypical symptoms.[15, 16] In the IRAD 
registry, also age ≥70 years and diabetes mellitus have been associated with delayed diagnosis.[15] Amongst 
clinical findings, painless presentation (up to 15% of cases), constitutes a major conundrum. Additional major 




In the ED, most patients with AAS-compatible symptoms are affected by more prevalent conditions, 
such as muscle-skeletal pain, gastrointestinal disease, coronary artery disease (CAD), primary stroke and 
syncope. For AASs, accurate biomarkers are not available and conclusive diagnosis requires advanced 
imaging. Contrast-enhanced tomography angiography (CTA) constitutes the key diagnostic tool for AASs in 
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the ED. However, CTA exposes patients to radiation, carries risks of allergy and kidney injury and may 
necessitate secondary transfer to hub centers. Hence, the key diagnostic problem is represented by proper 
selection of patients necessitating CTA. Accordingly, misdiagnosis of AASs has been described in 39% of cases, 
leading to worse outcomes.[21] 
 
Scenario 1: hemodynamic instability  
Presentation of AASs in the ED spans across three main clinical scenarios. Scenario 1 includes critical 
patients presenting with cardiocirculatory arrest, hemodynamic instability or shock state. According to IRAD 
data, systolic blood pressure <90 mmHg is found in 29% patients with AASs. Most of these patients are 
affected by AD complicated by rupture (28/26% type A/B) or pericardial tamponade (8%), severe myocardial 
ischemia (15%) or acute aortic regurgitation (12%).[22] In these patients, stabilization and advanced life 
support should be paralleled by bedside evaluation including 12-lead ECG and point-of-care ultrasonography 
(POCUS). The latter should focus on direct/indirect signs of AASs. Moreover, POCUS is useful for differential 
diagnosis with tension pneumothorax (lack of pleural sliding), massive pulmonary embolism (right ventricle 
overload), severe left-ventricular dysfunction (dilated/hypo-contractile LV), hypovolemic/septic shock 
(inferior vena cava collapse).[21, 23, 24]. In parallel to bedside evaluations, management must focus on 
organization/transfer to CTA, or directly to pre-surgical TEE in theater. 
 
Scenario 2: critical organ ischemia 
 Scenario 2 involves patients presenting to the ED with critical and time-dependent organ ischemia 
(myocardial or CNS). Overlap with scenario 1 is frequent, because hemodynamic instability and critical 
ischemia can be strictly interlaced. Presence of ST-segment elevation on ECG should be interpreted as a red-
flag for possible direct involvement of coronary ostia. In patients with type A AD, ST segment elevation in 
lead aVR has been specifically found as a predictor of in-hospital death.[19, 25, 26] However, ST elevation is 
found in only 15% of cases.[6] In these patients, administration of dual antiplatelet and anticoagulant therapy 
and coronary angiography are associated with delayed diagnosis and worse outcome (major bleeding 38% vs 
13%, in-hospital mortality 27% vs 13%).[27] Hence, in patients with ST elevation, rapid focused evaluation of 
the past and recent medical history for signs/symptoms of AASs, and rapid AAS-oriented POCUS may help 
identify a small minority of patients requiring urgent aortic imaging before proceeding with medical therapy 
and transfer to the cath-lab. This could be done by CTA or by evaluating with the interventional cardiologist 
the utility to perform aortography before standard coronary assessment and treatment.  
Nonetheless, physicians should be aware that ECG is frequently abnormal in all subtypes of AASs 
(42% in IRAD registry). Most patients will present non-ST elevation and unspecific patterns. In AASs, presence 
of substantial myocardial ischemia will substantially increase the risk of unfavourable outcome. and ECG 
alterations will increase the risks of misdiagnosis and mis-treatment.[27, 28] 
6 
 
An acute central neurologic deficit suggestive of stroke is found in 16% of patients with AASs.[29] 
However, AAS represents the cause of stroke in only 1% of patients.[30] Given the strict time limits for 
reperfusion therapy in ischemic stroke, systematic evaluation of the thoracic aorta (by POCUS/chest X-ray) 
in all patients is not recommended and may be even harmful. A pragmatic approach to limit the misdiagnosis 
in patients with suspected ischemic stroke is represented by systematic search for AASs risk factors and a 
scrupulous physical exam. In patients with risk factor(s) and clinical suspicion of AAS as the cause of stroke 
(e.g. pulse deficit or peri-ictal trunk pain), chest CTA should be considered concomitant to head-neck CTA 
scan. 
 
Scenario 3: non-critical presentation 
Scenario 3 involves patients without hemodynamic instability or critical organ ischemia. In the ED, 
this represents by far the most frequent scenario (70-80% of patients). With few exceptions, decision on 
advanced imaging can be postponed until availability of a full clinical picture, after completion of three steps: 
(1) pre-test probability assessment and clinical gestalt, (2) first-line imaging/POCUS, (3) blood tests with D-
dimer (for patients at low probability). In this common scenario, decision on CTA must overlap with clinical 
reasoning for differential diagnosis and programs for patient observation/discharge. 
 
Pre-test probability assessment 
In order to standardize assessment of the pre-test probability of AASs, 2010 AHA/ACC guidelines first 
adopted a risk score (Aortic Dissection Detection Risk Score, ADD-RS) developed on the IRAD registry and 
integrating 12 risk-markers organized in 3 categories: predisposing conditions, pain type, physical exam 
(figure 1).[1, 2, 31] The ADD-RS ranges from 0 to 3, based on the number of categories where at least one 
risk marker is present. The ADD-RS has been validated by several ED studies, including a large prospective 
study led by our group. In a recent metanalysis, ADD-RS≥1 provided a pooled sensitivity (sens) of 0.94 and a 
pooled specificity (spec) of 0.40. ADD-RS≥2 provided a sens of 0.46 and a spec of 0.91. Assuming a prevalence 
of AASs of 20%, ADD-RS≥1 has a failure rate of 3.8%, corresponding to 1 missed case in 26 patients.[32] 
Assuming a prevalence of 5%, the failure rate is 0.8%, corresponding to 1 missed case in 125. Hence, even in 
case of lower pre-test probability, ADD-RS per se is insufficient to safely rule-out the disease. 
AHA/ACC guidelines identify three groups of patients: ADD-RS=0 or low-risk, ADD-RS=1 or 
intermediate-risk, ADD-RS≥2 or high-risk. ESC guidelines suggest a dual classification: ADD-RS≤1 or low 
probability (low-P) and ADD-RS≥2 or high probability. Presence of ADD-RS≥2 warrants advanced aortic 
imaging irrespective of other findings, unless a clear alternative diagnosis is identified.[2] Instead, ADD-RS≤1 
identifies patients amenable to integrated clinical rule-out, in whom decision on CTA must be carefully 
weighted. These represent 80% of all patients with suspected AAS, and therefore heavily affect ED practice 





Direct albeit partial visualization of the thoracic and abdominal aorta may improve probability 
assessment in suspected AASs.[24, 33, 34] In order to perform POCUS at its best, patients must be in supine 
or left lateral decubitus, and the following views should be used by a trained physician: left/right parasternal, 
apical, suprasternal, subcostal, abdominal, view for carotid and iliac/femoral arteries.[3, 35] When applying 
a focused cardiac protocol, POCUS can be limited to the left parasternal and subcostal views. 
Direct US signs of AASs are: presence of an intimal flap, presence of IMH (circular/crescentic 
thickening of the aortic wall >5 mm) and presence of PAU (crater-like outpouching with jagged edges in the 
aortic wall). Indirect signs are: thoracic aorta dilatation (diameter ≥4 cm at any level), pericardial 
effusion/tamponade and aortic valve regurgitation at least moderate.[24, 34] Studies in the ED have shown 
that transthoracic echocardiography has a Sens/Spec of 88-90.9%/56-100% for AD-A and a sens/spec of 51-
81.9%/60-83% AD-B.[3, 23, 36–38] The diagnostic accuracy for other AAS types is even lower. In AD-B, a 
paravertebral approach might increase Sens to 80.9%, but technical feasibility is limited and ED validation is 
lacking.[39]  
The ADvISED trial has confirmed that even if combined with ADD-RS, POCUS has insufficient sens 
(93.8%) and failure rate (1.9%) to allow conclusive rule-out.[23, 40, 41] However, in this trial about 1 in 20 
patients at low-P showed direct signs of AASs, uncovering need for immediate CTA. Indirect POCUS signs 
were found in 28.6% of low-P patients, but the spec was low. Thus, in patients at low-P, identification of 




Chest X-ray (CR) is routinely performed in patients with truncal pain. Beyond providing alternative 
diagnoses to AASs (e.g. pneumonia, pneumothorax, free subphrenic air, costal or vertebral fracture), CXR can 
partially visualize the thoracic aorta and detect pathological findings, such as mediastinum enlargement (≥ 
80 mm at the aortic knob level or mediastinum/chest ratio 0.25) or more rare signs: double aortic knob, poor 
definition/irregularity of the aortic contour, displacement of aortic wall calcifications (>10 mm), right tracheal 
displacement, displacement of a nasogastric tube, left-sided pleural effusion, pericardial effusion and left 
apical opacity. However, CR is associated with low sens (60.4%) and spec (85.2%) for AASs and only marginally 
affects diagnostic decisions. A secondary analysis of the ADvISED study has shown that association of CR with 





AASs are associated with increased white blood cell count, increased neutrophil to lymphocyte ratio, 
reduced platelet count, increased platelet to lymphocyte ratio and reduced fibrinogen level. The largest 
changes are found in AD-A. The diagnostic accuracy of these findings is modest, even if combined. However, 
in patients at low clinical probability, they could be used to refine pre-test probability assessment.[44] In a 
large Chinese study, plasma sST2 showed high accuracy for AASs. However, a subsequent ED study applying 
a commercial assay has failed to confirm this data.[45, 46] 
Lactate dehydrogenase, troponin and C-reactive protein have negligible diagnostic accuracy. Instead, 
they are markers of organ malperfusion, myocardial malperfusion and secondary inflammation.[47, 48] For 
instance, elevated troponin has been reported in 26.8% of patients with AD and associated with increased 
short-term mortality.  
D-dimer is a degradation product of crosslinked fibrin, widely used as a rule-out biomarker of 
pulmonary embolism. Several studies have shown that D-dimer levels robustly increase in AASs.[2, 32, 49, 
50] At present, the only validated D-dimer cut-off for AASs is 500 ng/mL FEU, while only preliminary data 
have been provided for an age-adjusted cut-off.[14, 50, 51] D-dimer is characterized by high sens and low to 
moderate spec due to unspecific increase with age, cancer and several diseases in differential diagnosis (e.g. 
pericarditis, pleuritis, pneumonia, sepsis, pulmonary embolism). D-dimer can be falsely negative in very early 
or late presenters, in small IMHs and focal dissections.[50, 52] To allow optimal sens, D-dimer must be applied 
to patients at low-P to provide an acceptably low false negative rate (table 3).[49] 
 
Advanced imaging 
 Detailed description of advanced aortic imaging can be found elsewhere.[38] In the ED, the key 
advanced imaging exam is CTA, due to excellent diagnostic performance (sens/spec 98-100%), widespread 
availability, rapid execution and capacity of wide differential diagnosis. Whenever possible, CTA should be 
performed with cardiac gating, in order to reduce possible artefacts.[53] In patients without AASs and a 
suspicion of CAD or pulmonary embolism, concomitant coronary and/or pulmonary CTA should be 
considered, providing double/triple rule-out.[3] Magnetic resonance imaging also has high sens/spec coupled 
to absence of radiation exposure, but is inadequate for ED use due to prolonged scan time and limited 
availability. Finally, transoesophageal echocardiography also has also excellent diagnostic accuracy (sens 
98%, spec 95%) and is fundamental for intraoperative aortic valve evaluation, but has limited application in 
the ED due to insufficient power for differential diagnosis, and necessity of highly-trained physicians and 
sedation.[38, 54] In the ED, this tool essentially applies to patients with inconclusive CTA. 
 
Treatment 
After an AAS has been diagnosed, the key objective is to obtain a clear definition of the disease and 
activate local protocols for specialized therapeutic evaluation, while providing strict patient monitoring, 
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medical and supportive care. All patients should receive ECG, blood pressure and oxygen saturation 
monitoring, adequate venous access and possibly a urinary catheter, to monitor diuresis and to avoid Valsalva 
manoeuvres. If required, invasive arterial blood pressure monitoring should be inserted (preferably in the 
left radial artery). Oxygen saturation via pulse oximetry should be >95%, if needed with supplemental oxygen. 




In presence of shock, supportive treatment must be based on the presumable underlying cause: 
haemorrhage, cardiac tamponade or critical myocardial ischemia. Fluids (crystalloids, colloids, blood 
transfusion) should be used to increase cardiac pre-load and output. Critical patients receiving anticoagulants 
should receive proper reversal agents. In tamponade, emergency pericardiocentesis is relatively 
contraindicated due to a high risk of futility (potential interference with pericardial clotting). Accordingly, 
pericardiocentesis is indicated (2010 AHA guidelines) in case of severe hemodynamic instability incompatible 
with surgical timing (cardiac arrest or peri-arrest) and in fluid-refractory shock. Drainage of even small 
quantities of blood (e.g. 40 ml) may obtain a positive hemodynamic effect.[1, 2] Vasoactive amines may be 
used with caution. There are no clear recommendations regarding the blood pressure target to be obtained. 
Ideally, physicians should aim to ensure critical organ perfusion while minimizing stress on the damaged 
aortic wall. The 2010 AHA guidelines target permissive hypotension (mean arterial pressure 70 mmHg).[1, 2] 
In presence of decompensated acute heart failure, fluids could precipitate pulmonary edema and should be 
restricted. 
 
Pain and anti-impulse therapy 
Optimal medical therapy is recommended in all patients (class I/C).[2] Pragmatically, pain control 
with opioids (table 4) constitutes the first therapeutic line and must be considered even in the earlier phases, 
before a conclusive diagnosis is obtained. Opioids provide beneficial effects also on agitation, dyspnoea, 
respiratory distress and hemodynamic state, due to sedation and reduction in the adrenergic component.[1, 
2] The visual analogue pain scale target is <4. Pain control must be rapid while avoiding excessive sedation, 
respiratory depression and vomiting. Opioids are relatively contraindicated by shock, but case-by-case 
evaluation will be necessary in very severe patients, for whom advanced treatments may be futile. 
 In patients without hypotension, aortic damage and organ malperfusion may be reduced by 
administration of an early anti-impulse therapy based on simultaneous reduction of heart rate and blood 
pressure. Anti-impulse therapy has the purpose of decreasing the aortic pulsatility and wall stress, delaying 
the tearing process and preventing rupture. This therapy also improves myocardial perfusion by decreasing 
post-load and oxygen consumption. Targets of anti-impulse therapy are a heart rate of 55-66 bpm and a 
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systolic blood pressure of 100-120 mmHg, within minutes. This should not be achieved at the expense of 
hemodynamic stability and organ perfusion (especially cerebral flow in case of neurological deficit). 
Treatment should begin as soon as possible and must continue until the patient is transferred to a specialized 
unit or to the operating theatre.[3] 
Unfortunately, there are few low-quality comparative studies and no randomized trials supporting 
recommendations for anti-impulse therapy. First-line drugs are intravenous beta-blockers (table 4). In the 
ED, labetalol represents an ideal and manageable drug providing both heart rate control and vasodilation. In 
case of absolute contraindications (rarely encountered), alternative options are calcium channel blockers, 
urapidil or clonidine. If target blood pressure is not obtained after titration of a beta-blocker and after 
assuring adequate heart rate control, a vasodilator should be added (nitroprusside or nitro-glycerine). Single 
use of a vasodilator is not recommended, in order to avoid reflex tachycardia aggravating wall stress.  
 
Surgical and interventional treatment 
Advanced imaging must provide crucial information for severity stratification and therapeutic 
planning. For all patients, early communication and collaboration with an aortic specialist/team should be 
engaged. Based on local availability, teleconsultations may constitute an ideal strategy to improve 
management and to define the best modalities/timing for secondary transfer. Referral to high-volume 
centres has been shown to increase survival rate. Therefore, regional protocols governing patient referral 
and transfer should be developed and implemented.[2, 55] 
 
Type A acute aortic syndromes 
In patients with AD/IMH-A, urgent cardiovascular surgery represents as the main and time-
dependent therapeutic option (class I/B). In these patients, ED management should focus on patient support 
and preparation for surgery (including request of compatible blood units). 
In AAS-IIA, surgical treatment will remove the AD entry breach/hematoma, replacing the ascending 
aorta with a vascular graft. Ascending aorta replacement may require reimplantation of the coronary hosts 
and/or repair/replacement of the aortic valve. In case of extensive aortic root involvement or dilatation, 
patients may require replacement of the aortic bulb, with preservation of the valve (valve sparing technique: 
reimplantation according to Tirone David V or remodelling according to Yacoub), or complete replacement 
of the aortic bulb and valve with a tube-valve conduit (Bentall technique). Reinforcement of the aortic wall 
at the level of the distal anastomosis and/or the non-coronary sinuses can be obtained by application of a 
Teflon strip (Bavaria technique). 
In AD-IA, the primary entrance breach is in the ascending aorta in 65% of patients. In these cases, 
surgical treatment will as in AD-IIA. This will restore antegrade flow in the aortic TL and decompress/seal the 
FL. In 35% of cases, the entry breach is located within the aortic arch, thus requiring more extensive 
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interventions such as hemi-arch/total arch replacement with re-implantation of the supra-aortic trunks 
(island technique-Carrell patch or trifurcated protheses) or debranching on the surgical graft in the ascending 
aorta. In order to reduce flux in the distal FL and facilitate subsequent interventions, an additional aortic 
endograft can be positioned distally in the descending aorta (elephant or frozen elephant trunk). 
These surgical treatments require an extracorporeal circulation. Currently, the most frequently used 
arterial cannulation site is the right axillary artery. Systemic arrest with cerebral and multi-organic protection 
through hypothermia and retrograde or selectively antegrade cerebral perfusion are needed. This also allows 
inspection of the aortic arch and evaluation of the most suitable surgical technique on a case-by-case 
basis.[56] During these procedures, continuous monitoring of brain function is performed. Based on IRAD 
data, in-hospital mortality for operated AD-A is 23.6%.[57]  
 
Type B acute aortic syndromes 
All patients with AAS-B require medical therapy (class I/C), aiming at immediate and long-term pain 
control, hemodynamic stabilization and organ perfusion, with continuous drug infusions. A minority of 
patients will also require urgent interventional treatment, pending expert integration of imaging and clinical 
data on site, by teleconsultation or following patient transfer, based on local protocols. Endovascular or 
surgical interventions must be considered in patients presenting severe aortic dilatation, signs of impending 
rupture, aortic rupture and organ malperfusion. These conditions, together with persistence of severe pain 
and refractory hypertension, define a status of “complicated” AD-B and warrant thoracic endovascular aortic 
repair (TEVAR, class I/C, as compared to IIb/C for surgery). In “uncomplicated” AAS-B, TEVAR is not indicated 
as a first line strategy and the key priority will be patient transfer to an intensive care unit or high-dependency 
unit, to continue optimized medical therapy, continuous monitoring and re-assessment. Subsequent TEVAR 
may be considered based on long-term risk/benefit evaluation (class IIa/B). Based on IRAD data, in-hospital 
mortality for type B AD is 23% if surgically treated, 10.8% if TEVAR-treated. [57] 
TEVAR is meant to cover the entry breach, induce FL closure and thrombosis, stabilize the aorta and 
prevent further aortic dilatation. The graft is typically landed distal to the LSA (LSA), or between the LSA and 
the left common carotid artery on a segment of non-dissected aorta, and is extended for 15 cm or longer. 
The main complications associated with TEVAR are paraplegia (2.8%), retrograde AD-A (2.5%) and stent graft-
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Table 1. Risk factors for acute aortic syndromes. 
 
Long-term history Recent history 
Genetic conditions Multifactorial conditions 
Marfan, Ehlers-Danlos (vascular 





Familial history of thoracic aorta 
aneurysm or aortic dissection 
Vasculitis (Takayasu, Giant cell, 
Behçet arteritis)  
Trauma and accident with strong 
deceleration or torsion (e.g. 
motor vehicle, fall from height) 
Bicuspid aortic valve Pheochromocytoma Use of cocaine, amphetamines or 
other stimulant drugs 
Polycystic kidney disease Infective aortitis Recent fluoroquinolone use 
Aortic coartation Poorly controlled hypertension Recent aortic manipulation 
(interventional procedures or 
aortic surgery) 
Chronic treatment with steroids 
or immunosuppressants 
Uncontrolled hypertension 




Previous aortic interventions 
(surgery, endovascular) 







Table 2. Diagnostic performance of clinical sings/symptoms for acute aortic syndromes. 
Clinical findings IRAD[11] database Ohle[12] metanalysis ADViSED[13] trial 
Presenting symptoms 
Chest pain 
  Sens 











  Sens 










  Sens 










  Sens 









Focal neurological deficit 
  Sens 











  Sens 










  Sens 










  Sens 










  Sens 




















  Spec 91 95.9 
Hypotension 
  Sens 










  Sens 














Table 3. Test characteristics of D-dimer for diagnosis of acute aortic syndromes in metanalyses. 
 
 D-dimer <500 ng/mL ADD-RS≤1 + D-dimer <500 ng/mL 
Author Asha et al.[52] Tsutsumi et al.[32] Bima et al.[14] 
Sens 0.98 (0.96-0.99) 1.00 (0.99-1.00) 0.98 (0.97-0.99) 
Spec 0.42 (0.39-0.45) 0.15 (0.13-0.18) 0.43 (0.31-0.56) 
LR- 0.05 (0.02-0.09) 0.01 (0.00-0.07) 0.025 (0.001-0.049) 









   Morphine 1-4 mg/kg bolus (up to 10 mg every 4 h) 




   Esmolol (β1-blocker)1 0.5-1 mg/kg bolus, followed by 0.05-0.3 mg/kg/min 
infusion (titrate by 0.1 mg/Kg/min) 
   Labetalol (β1/2, α1-blocker)1 20 mg bolus (may repeat 20-80 mg every 10 min, up 
to 300 mg), or 30-120 mg/h infusion 
   Metoprolol (β1-blocker)2 5 mg bolus (may repeat after 5 min, up to 15 mg) 
   Propranolol (β1/2-blocker)2 1-3 mg bolus (may repeat after 5 min, up to 5 mg) 
  
Calcium channel blockers 
   Verapamil2 5-10 mg bolus (may repeat after 5-10 min) 
 
   Diltiazem2 5-20 mg bolus (may repeat after 15 min), 5-15 mg/h 
infusion 
  
Centrally acting sympatholytic drug  
   Clonidin (central α2-presynaptic agonist)2 0.15-0.3 mg (may repeat after 40 min) 
  
Vasodilators  
   Sodium nitroprusside1 0.25-0.5 g/kg/min infusion (titrate up to 10 
g/min) 
   Nitroglycerine2 5-200 g/min infusion 
   Urapidil (α1-blocker, central 5HT1A agonist) 12.5-25 mg bolus, 5-40 mg/h infusion 
 






Figure 1. Integrated algorithm for diagnosis and management of acute aortic syndromes. 
 
